Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study.

Böger RH, Skamira C, Bode-Böger SM, Brabant G, von zur Muhlen A, Frolich JC

The Journal of clinical investigation1 Dec 1996Cited by 177 (Europe PMC)

PMID8981915PMCIDPMC507734DOI10.1172/jci119095PepBankPUB-08981915

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanNon-randomized trialEfficacy outcome
In adults with acquired GH deficiency, r-hGH increased plasma IGF-1 fourfold within the first month.
In plain wordsIn adults with acquired GH deficiency, plasma IGF-1 increased fourfold during r-hGH treatment.
Peptide
HGH (somatotropin)
Outcome
IncreasePlasma IGF-1
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
2.0 IU/d · 1 monthAs given in this study (human).
Measurements
Plasma IGF-1 increase
4 fold
within first month of r-hGH treatment
Source sentences
Summary
r-hGH induced a fourfold increase in plasma IGF-1 concentrations within the first month of treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
We studied the effects of recombinant growth hormone on systemic nitric oxide (NO) formation and hemodynamics in a double-blind, placebo-controlled trial in adult patients with acquired growth hormone deficiency.
Summary · context
30 patients were randomly allocated to either recombinant human growth hormone (r-hGH; 2.0 IU/d) or placebo for 12 mo.
Summary · context
In the subsequent 12 mo, the study was continued with both groups of patients receiving r-hGH.
Report a problemFND-0898191501
02HumanNon-randomized trialEfficacy outcome
In adults with acquired GH deficiency, r-hGH significantly increased urinary nitrate excretion during each group's first 12 months of treatment.
In plain wordsIn adults with acquired GH deficiency, urinary nitrate excretion increased during r-hGH treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseUrinary nitrate excretion
Study
n: not reported in source
Outcome group
Nitric Oxide Production · Cardiovascular
Studied dose
2.0 IU/d · 12 monthsAs given in this study (human).
Measurements
Urinary nitrate excretion
96.8 micromol/mmol creatinine
GH-deficient patients, baseline
Urinary nitrate excretion
167.3 micromol/mmol creatinine
healthy controls
Source sentences
Summary
These indices of NO production were significantly increased by r-hGH, within the first 12 mo in the GH group, and within the second 12 mo in the placebo group.
4 context sentences(design, population, supporting numbers)
Summary · context
Urinary nitrate and cyclic GMP excretion rates were low at baseline in growth hormone-deficient patients (nitrate, 96.8+/-7.4 micromol/mmol creatinine; cyclic GMP, 63.6+/-7.1 nmol/mmol creatinine) as compared with healthy controls (nitrate, 167.3+/-7.5 micromol/mmol creatinine; cyclic GMP, 155.2+/-6…
Summary · context
We studied the effects of recombinant growth hormone on systemic nitric oxide (NO) formation and hemodynamics in a double-blind, placebo-controlled trial in adult patients with acquired growth hormone deficiency.
Summary · context
30 patients were randomly allocated to either recombinant human growth hormone (r-hGH; 2.0 IU/d) or placebo for 12 mo.
Summary · context
In the subsequent 12 mo, the study was continued with both groups of patients receiving r-hGH.
Report a problemFND-0898191502
03HumanNon-randomized trialEfficacy outcome
In adults with acquired GH deficiency, r-hGH significantly increased urinary cyclic GMP excretion during each group's first 12 months of treatment.
In plain wordsIn adults with acquired GH deficiency, urinary cyclic GMP excretion increased during r-hGH treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseUrinary cyclic GMP excretion
Study
n: not reported in source
Outcome group
Nitric Oxide Production · Cardiovascular
Studied dose
2.0 IU/d · 12 monthsAs given in this study (human).
Measurements
Urinary cyclic GMP excretion
63.6 nmol/mmol creatinine
GH-deficient patients, baseline
Urinary cyclic GMP excretion
155.2 nmol/mmol creatinine
healthy controls
Source sentences
Summary
These indices of NO production were significantly increased by r-hGH, within the first 12 mo in the GH group, and within the second 12 mo in the placebo group.
4 context sentences(design, population, supporting numbers)
Summary · context
Urinary nitrate and cyclic GMP excretion rates were low at baseline in growth hormone-deficient patients (nitrate, 96.8+/-7.4 micromol/mmol creatinine; cyclic GMP, 63.6+/-7.1 nmol/mmol creatinine) as compared with healthy controls (nitrate, 167.3+/-7.5 micromol/mmol creatinine; cyclic GMP, 155.2+/-6…
Summary · context
We studied the effects of recombinant growth hormone on systemic nitric oxide (NO) formation and hemodynamics in a double-blind, placebo-controlled trial in adult patients with acquired growth hormone deficiency.
Summary · context
30 patients were randomly allocated to either recombinant human growth hormone (r-hGH; 2.0 IU/d) or placebo for 12 mo.
Summary · context
In the subsequent 12 mo, the study was continued with both groups of patients receiving r-hGH.
Report a problemFND-0898191503
04HumanNon-randomized trialEfficacy outcome
In adults with acquired GH deficiency, r-hGH did not significantly alter systolic blood pressure.
In plain wordsIn adults with acquired GH deficiency, systolic blood pressure did not change significantly during r-hGH treatment.
Peptide
HGH (somatotropin)
Outcome
No significant changeSystolic blood pressure
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Studied dose
2.0 IU/dAs given in this study (human).
Source sentences
Summary
While systolic and diastolic blood pressure were not significantly altered by r-hGH, cardiac output significantly increased by 30-40%, and total peripheral resistance decreased by approximately 30% in both groups when they were assigned to r-hGH treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
We studied the effects of recombinant growth hormone on systemic nitric oxide (NO) formation and hemodynamics in a double-blind, placebo-controlled trial in adult patients with acquired growth hormone deficiency.
Summary · context
30 patients were randomly allocated to either recombinant human growth hormone (r-hGH; 2.0 IU/d) or placebo for 12 mo.
Summary · context
In the subsequent 12 mo, the study was continued with both groups of patients receiving r-hGH.
Report a problemFND-0898191504
05HumanNon-randomized trialEfficacy outcome
In adults with acquired GH deficiency, r-hGH did not significantly alter diastolic blood pressure.
In plain wordsIn adults with acquired GH deficiency, diastolic blood pressure did not change significantly during r-hGH treatment.
Peptide
HGH (somatotropin)
Outcome
No significant changeDiastolic blood pressure
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Studied dose
2.0 IU/dAs given in this study (human).
Source sentences
Summary
While systolic and diastolic blood pressure were not significantly altered by r-hGH, cardiac output significantly increased by 30-40%, and total peripheral resistance decreased by approximately 30% in both groups when they were assigned to r-hGH treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
We studied the effects of recombinant growth hormone on systemic nitric oxide (NO) formation and hemodynamics in a double-blind, placebo-controlled trial in adult patients with acquired growth hormone deficiency.
Summary · context
30 patients were randomly allocated to either recombinant human growth hormone (r-hGH; 2.0 IU/d) or placebo for 12 mo.
Summary · context
In the subsequent 12 mo, the study was continued with both groups of patients receiving r-hGH.
Report a problemFND-0898191505
06HumanNon-randomized trialEfficacy outcome
In adults with acquired GH deficiency, cardiac output increased significantly by 30-40% during r-hGH treatment.
In plain wordsIn adults with acquired GH deficiency, cardiac output increased by 30-40% during r-hGH treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseCardiac output
Study
n: not reported in source
Outcome group
Heart function · Cardiovascular
Studied dose
2.0 IU/dAs given in this study (human).
Measurements
Cardiac output increase
30 to 40%
both groups when assigned to r-hGH
Source sentences
Summary
While systolic and diastolic blood pressure were not significantly altered by r-hGH, cardiac output significantly increased by 30-40%, and total peripheral resistance decreased by approximately 30% in both groups when they were assigned to r-hGH treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
We studied the effects of recombinant growth hormone on systemic nitric oxide (NO) formation and hemodynamics in a double-blind, placebo-controlled trial in adult patients with acquired growth hormone deficiency.
Summary · context
30 patients were randomly allocated to either recombinant human growth hormone (r-hGH; 2.0 IU/d) or placebo for 12 mo.
Summary · context
In the subsequent 12 mo, the study was continued with both groups of patients receiving r-hGH.
Report a problemFND-0898191506
07HumanNon-randomized trialEfficacy outcome
In adults with acquired GH deficiency, total peripheral resistance decreased by approximately 30% during r-hGH treatment.
In plain wordsIn adults with acquired GH deficiency, total peripheral resistance decreased by approximately 30% during r-hGH treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseTotal peripheral resistance
Study
n: not reported in source
Outcome group
Heart function · Cardiovascular
Studied dose
2.0 IU/dAs given in this study (human).
Measurements
Total peripheral resistance decrease
≈ 30%
both groups when assigned to r-hGH
Source sentences
Summary
While systolic and diastolic blood pressure were not significantly altered by r-hGH, cardiac output significantly increased by 30-40%, and total peripheral resistance decreased by approximately 30% in both groups when they were assigned to r-hGH treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
We studied the effects of recombinant growth hormone on systemic nitric oxide (NO) formation and hemodynamics in a double-blind, placebo-controlled trial in adult patients with acquired growth hormone deficiency.
Summary · context
30 patients were randomly allocated to either recombinant human growth hormone (r-hGH; 2.0 IU/d) or placebo for 12 mo.
Summary · context
In the subsequent 12 mo, the study was continued with both groups of patients receiving r-hGH.
Report a problemFND-0898191507
08HumanNon-randomized trialEfficacy outcome
In adults with acquired GH deficiency, second-year plasma IGF-1 did not differ significantly between initial groups when both received r-hGH.
In plain wordsIn adults with acquired GH deficiency, plasma IGF-1 did not differ between initial groups during second-year r-hGH treatment.
Peptide
HGH (somatotropin)
Outcome
No significant changeSecond-year plasma IGF-1
Study
n: not reported in source
Comparator
Patients initially assigned placebo, now receiving r-hGH
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
2.0 IU/dAs given in this study (human).
Source sentences
Summary
In the second study year, when both groups were given r-hGH, there were no significant differences in plasma IGF-1, urinary nitrate, or cyclic GMP excretion, or hemodynamic parameters between both groups.
3 context sentences(design, population, supporting numbers)
Summary · context
We studied the effects of recombinant growth hormone on systemic nitric oxide (NO) formation and hemodynamics in a double-blind, placebo-controlled trial in adult patients with acquired growth hormone deficiency.
Summary · context
30 patients were randomly allocated to either recombinant human growth hormone (r-hGH; 2.0 IU/d) or placebo for 12 mo.
Summary · context
In the subsequent 12 mo, the study was continued with both groups of patients receiving r-hGH.
Report a problemFND-0898191508
09HumanNon-randomized trialEfficacy outcome
In adults with acquired GH deficiency, second-year urinary nitrate did not differ significantly between initial groups when both received r-hGH.
In plain wordsIn adults with acquired GH deficiency, urinary nitrate did not differ between initial groups during second-year r-hGH treatment.
Peptide
HGH (somatotropin)
Outcome
No significant changeSecond-year urinary nitrate
Study
n: not reported in source
Comparator
Patients initially assigned placebo, now receiving r-hGH
Outcome group
Receptor activity and mechanism · Cardiovascular
Studied dose
2.0 IU/dAs given in this study (human).
Source sentences
Summary
In the second study year, when both groups were given r-hGH, there were no significant differences in plasma IGF-1, urinary nitrate, or cyclic GMP excretion, or hemodynamic parameters between both groups.
3 context sentences(design, population, supporting numbers)
Summary · context
We studied the effects of recombinant growth hormone on systemic nitric oxide (NO) formation and hemodynamics in a double-blind, placebo-controlled trial in adult patients with acquired growth hormone deficiency.
Summary · context
30 patients were randomly allocated to either recombinant human growth hormone (r-hGH; 2.0 IU/d) or placebo for 12 mo.
Summary · context
In the subsequent 12 mo, the study was continued with both groups of patients receiving r-hGH.
Report a problemFND-0898191509
10HumanNon-randomized trialEfficacy outcome
In adults with acquired GH deficiency, second-year cyclic GMP excretion did not differ significantly between initial groups when both received r-hGH.
In plain wordsIn adults with acquired GH deficiency, cyclic GMP excretion did not differ between initial groups during second-year r-hGH treatment.
Peptide
HGH (somatotropin)
Outcome
No significant changeSecond-year cyclic GMP
Study
n: not reported in source
Comparator
Patients initially assigned placebo, now receiving r-hGH
Outcome group
Receptor activity and mechanism · Cardiovascular
Studied dose
2.0 IU/dAs given in this study (human).
Source sentences
Summary
In the second study year, when both groups were given r-hGH, there were no significant differences in plasma IGF-1, urinary nitrate, or cyclic GMP excretion, or hemodynamic parameters between both groups.
3 context sentences(design, population, supporting numbers)
Summary · context
We studied the effects of recombinant growth hormone on systemic nitric oxide (NO) formation and hemodynamics in a double-blind, placebo-controlled trial in adult patients with acquired growth hormone deficiency.
Summary · context
30 patients were randomly allocated to either recombinant human growth hormone (r-hGH; 2.0 IU/d) or placebo for 12 mo.
Summary · context
In the subsequent 12 mo, the study was continued with both groups of patients receiving r-hGH.
Report a problemFND-0898191510
11HumanNon-randomized trialEfficacy outcome
In adults with acquired GH deficiency, second-year hemodynamic parameters did not differ significantly between initial groups when both received r-hGH.
In plain wordsIn adults with acquired GH deficiency, hemodynamic parameters did not differ between initial groups during second-year r-hGH treatment.
Peptide
HGH (somatotropin)
Outcome
No significant changeSecond-year hemodynamic parameters
Study
n: not reported in source
Comparator
Patients initially assigned placebo, now receiving r-hGH
Outcome group
Heart function · Cardiovascular
Studied dose
2.0 IU/dAs given in this study (human).
Source sentences
Summary
In the second study year, when both groups were given r-hGH, there were no significant differences in plasma IGF-1, urinary nitrate, or cyclic GMP excretion, or hemodynamic parameters between both groups.
3 context sentences(design, population, supporting numbers)
Summary · context
We studied the effects of recombinant growth hormone on systemic nitric oxide (NO) formation and hemodynamics in a double-blind, placebo-controlled trial in adult patients with acquired growth hormone deficiency.
Summary · context
30 patients were randomly allocated to either recombinant human growth hormone (r-hGH; 2.0 IU/d) or placebo for 12 mo.
Summary · context
In the subsequent 12 mo, the study was continued with both groups of patients receiving r-hGH.
Report a problemFND-0898191511

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT00470002

Effects of Growth Hormone on the Nitric Oxide Pathway

Hannover Medical Schooln = 16May 2004 to Jan 2005

Cardiovascular Disease

Trial page ClinicalTrials.govUpdated 7 May 2007

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.